MIR.V Stock - MedMira Inc.
Unlock GoAI Insights for MIR.V
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $240,509 | $412,568 | $432,529 | $952,127 | $2.14M |
| Gross Profit | $-990,255 | $226,489 | $-434,911 | $304,027 | $1.72M |
| Gross Margin | -411.7% | 54.9% | -100.6% | 31.9% | 80.3% |
| Operating Income | $-3,589,747 | $-2,572,996 | $-1,944,318 | $-1,453,222 | $-184,232 |
| Net Income | $-4,524,407 | $-3,326,321 | $-2,675,658 | $-1,831,576 | $-675,797 |
| Net Margin | -1881.2% | -806.2% | -618.6% | -192.4% | -31.5% |
| EPS | $-0.01 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
Visit WebsiteEarnings History & Surprises
MIR.VEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | — | — | — | — |
Q4 2025 | Dec 29, 2025 | — | — | — | — |
Q3 2025 | Jul 1, 2025 | — | — | — | — |
Q1 2025 | Mar 31, 2025 | — | $-0.00 | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.00 | — | — |
Q4 2024 | Dec 27, 2024 | — | $-0.00 | — | — |
Q3 2024 | Jul 3, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 2, 2024 | — | $-0.00 | — | — |
Q1 2024 | Feb 9, 2024 | — | $-0.00 | — | — |
Q4 2023 | Dec 29, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q4 2022 | Nov 30, 2022 | — | $-0.00 | — | — |
Q3 2022 | Jul 31, 2022 | — | $-0.00 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-0.00 | — | — |
Q1 2022 | Jan 31, 2022 | — | $-0.00 | — | — |
Q4 2021 | Oct 31, 2021 | — | $-0.00 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-0.00 | — | — |
Q2 2021 | Apr 30, 2021 | — | $-0.00 | — | — |
Latest News
Frequently Asked Questions about MIR.V
What is MIR.V's current stock price?
What is the analyst price target for MIR.V?
What sector is MedMira Inc. in?
What is MIR.V's market cap?
Does MIR.V pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MIR.V for comparison